-Universitätsklinikder

[117] Nauck, F., Eulitz, N. (2007). Tumorschmerztherapie: Basistherapie und
Behandlung des Durchbruchschmerzes. Der Schmerz 21 (4), 359–372
[118] Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A.,
Parlow, J. L., Boyce, S. W., Verburg, K. M. (2005). Complications of the
COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J.
Med. 352 (11), 1081–1091
[119] Oldenmenger, W. H., Sillevis Smitt, P. A. E., van Dooren, S., Stoter, G., van
der Rijt, C. C. D. (2009). A systematic review on barriers hindering
adequate cancer pain management and interventions to reduce them: a
critical appraisal. Eur. J. Cancer 45 (8), 1370–1380
[120] Oosterling, A., Boveldt, N. te, Verhagen, C., van der Graaf, W. T., Van
Ham, M., Van der Drift, M., Vissers, K., Engels, Y. (2015). Neuropathic Pain
Components in Patients with Cancer: Prevalence, Treatment, and
Interference with Daily Activities. Pain Practice, 1–9
[121] Orhan, M. E., Bilgin, F., Ergin, A., Dere, K., Güzeldemir, M. E. (2008). [Pain
treatment practice according to the WHO analgesic ladder in cancer
patients: eight years experience of a single center]. Agri 20 (4), 37–43
[122] O’Toole, T. M., Schmulewitz, N. (2009). Complication rates of EUS-guided
celiac plexus blockade and neurolysis: results of a large case series.
Endoscopy 41 (7), 593–597
[123] Palos, G. R., Mendoza, T. R., Mobley, G. M., Cantor, S. B., Cleeland, C. S.
(2006). Asking the community about cutpoints used to describe mild,
moderate, and severe pain. J Pain 7 (1), 49–56
[124] Paul, S. M., Zelman, D. C., Smith, M., Miaskowski, C. (2005). Categorizing
the severity of cancer pain: further exploration of the establishment of
cutpoints. Pain 113 (1-2), 37–44
[125] Payne, R. (1989). Cancer pain. Anatomy, physiology, and pharmacology.
Cancer 63 (11), 2266–2274
74